Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Cognitive tests and assessment

Topic: Brain proteins, microglia and lab models

Plain-language summary

Background Parkinsonian syndrome related to intravenous use of a "designer" psychostimulant, derived from pseudoephedrine using potassium permanganate as the oxidant, has been observed in drug addicts in Estonia. Objective To describe the symptomatology of four young patients, history of drug administration and chemical analysis of a drug batch. Methods Mental and motor function and quality of life were scored and ephedrone was analyzed using electrospray mass spectrometry.

What this study adds

Evidence grade: Low

This report describes four young drug addicts with irreversible parkinsonian syndrome related to intravenous use of a psychostimulant derived from pseudoephedrine using potassium permanganate. None of the four cases scored below the dementia threshold in MMSE, and this is a small descriptive case series, not a study of Alzheimer's treatment, cure, or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sikk, K., Taba, P., Haldre, S., Bergquist, J., Nyholm, D., Zjablov, G., et al. (2007). Irreversible motor impairment in young addicts--ephedrone, manganism or both? Acta neurologica Scandinavica. https://doi.org/10.1111/j.1600-0404.2007.00818.x

Vancouver

Sikk K, Taba P, Haldre S, Bergquist J, Nyholm D, Zjablov G, et al. Irreversible motor impairment in young addicts--ephedrone, manganism or both? Acta neurologica Scandinavica. 2007. doi:10.1111/j.1600-0404.2007.00818.x. PMID: 17511846.

BibTeX

@article{sikk2007-17511846,
  author  = {Sikk, K. and Taba, P. and Haldre, S. and Bergquist, J. and Nyholm, D. and Zjablov, G. and Asser, T. and Aquilonius, S. M.},
  title   = {{Irreversible motor impairment in young addicts--ephedrone, manganism or both?}},
  journal = {Acta neurologica Scandinavica},
  year    = {2007},
  doi     = {10.1111/j.1600-0404.2007.00818.x},
  pmid    = {17511846},
  url     = {https://doi.org/10.1111/j.1600-0404.2007.00818.x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This report describes four young drug addicts with irreversible parkinsonian syndrome related to intravenous use of a psychostimulant derived from pseudoephedrine using potassium permanganate. None of the four cases scored below the dementia threshold in MMSE, and this is a small descriptive case series, not a study of Alzheimer's treatment, cure, or prevention.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Acta neurologica Scandinavica)
Journal's citation record 2 / 4 Acta Neurologica Scandinavica: journal h-index 160 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2007 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 665 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 31.7 citations a year over 21 year(s) since 2007
Impact for its field and year 5 / 6 Cited 30.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 2 / 4 Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Sten‐Magnus Aquilonius: h-index 44 (OpenAlex, whole career)
Institution's track record 1 / 3 Uppsala University: institution h-index 1,114 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 17511846)
Free to read 0 / 2 Behind a paywall — scores zero
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Cognitive tests and assessment from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →